{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:49:00Z","timestamp":1781423340063,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41417-018-0020-7","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T18:03:51Z","timestamp":1525370631000},"page":"184-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer"],"prefix":"10.1038","volume":"25","author":[{"given":"Kazuho","family":"Inoko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuna","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kushibiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hontani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsuchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Shichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry E","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-911X","authenticated-orcid":false,"given":"Noriyuki","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"20_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913\u201321.","journal-title":"Cancer Res"},{"key":"20_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1056\/NEJMra1404198","volume":"371","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039\u201349.","journal-title":"N Engl J Med"},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrclinonc.2013.66","volume":"10","author":"J Werner","year":"2013","unstructured":"Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"20_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"20_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"20_CR7","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.3748\/wjg.v19.i42.7461","volume":"19","author":"Y Chen","year":"2013","unstructured":"Chen Y, Sun XJ, Jiang TH, Mao AW. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol. 2013;19:7461\u201371.","journal-title":"World J Gastroenterol"},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jgm.2698","volume":"15","author":"SL Ginn","year":"2013","unstructured":"Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012\u2014an update. J Gene Med. 2013;15:65\u201377.","journal-title":"J Gene Med"},{"key":"20_CR9","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(13)70173-6","volume":"14","author":"MK Brenner","year":"2013","unstructured":"Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an empty suit? Lancet Oncol. 2013;14:e447\u201356.","journal-title":"Lancet Oncol"},{"key":"20_CR10","doi-asserted-by":"publisher","unstructured":"Singh HM, Ungerechts G, Tsimberidou AM. Gene and cell therapy for pancreatic cancer. Expert Opin Biol Ther. 2015; https:\/\/doi.org\/10.1517\/14712598.2015.1001734","DOI":"10.1517\/14712598.2015.1001734"},{"key":"20_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658\u201370.","journal-title":"Nat Biotechnol"},{"key":"20_CR12","first-page":"555","volume":"9","author":"JR Hecht","year":"2003","unstructured":"Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, et al. A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003;9:555\u201361.","journal-title":"Clin Cancer Res"},{"key":"20_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.gie.2011.10.007","volume":"75","author":"JR Hecht","year":"2012","unstructured":"Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I\/II study. Gastrointest Endosc. 2012;75:332\u20138.","journal-title":"Gastrointest Endosc"},{"key":"20_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","volume":"31","author":"JM Herman","year":"2013","unstructured":"Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, et al. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013;31:886\u201394.","journal-title":"J Clin Oncol"},{"key":"20_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/cgt.2010.65","volume":"18","author":"A Nakao","year":"2011","unstructured":"Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011;18:167\u201375.","journal-title":"Cancer Gene Ther"},{"key":"20_CR16","doi-asserted-by":"publisher","unstructured":"Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther. 2016; https:\/\/doi.org\/10.1038\/mt.2016.66","DOI":"10.1038\/mt.2016.66"},{"key":"20_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/104303403321070810","volume":"14","author":"WJ Wang","year":"2003","unstructured":"Wang WJ, Tai CK, Kasahara N, Chen TC. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther. 2003;14:117\u201327.","journal-title":"Hum Gene Ther"},{"key":"20_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ymthe.2005.03.017","volume":"12","author":"CK Tai","year":"2005","unstructured":"Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther. 2005;12:842\u201351.","journal-title":"Mol Ther"},{"key":"20_CR19","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.3171\/foc.2006.20.1.8","volume":"20","author":"W Wang","year":"2006","unstructured":"Wang W, Tai CK, Kershaw AD, Solly SK, Klatzmann D, Kasahara N, et al. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus. 2006;20:E25.","journal-title":"Neurosurg Focus"},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/cgt.2010.17","volume":"17","author":"CK Tai","year":"2010","unstructured":"Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF, et al. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer Gene Ther. 2010;17:614\u201323.","journal-title":"Cancer Gene Ther"},{"key":"20_CR21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/mt.2012.83","volume":"20","author":"OD Perez","year":"2012","unstructured":"Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther. 2012;20:1689\u201398.","journal-title":"Mol Ther"},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","volume":"8","author":"TF Cloughesy","year":"2016","unstructured":"Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016;8:341ra75.","journal-title":"Sci Transl Med"},{"key":"20_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/neuonc\/nor199","volume":"14","author":"D Ostertag","year":"2012","unstructured":"Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvao da Silva AP, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012;14:145\u201359.","journal-title":"Neuro Oncol"},{"key":"20_CR24","doi-asserted-by":"publisher","unstructured":"Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, et al. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol. 2017; https:\/\/doi.org\/10.1093\/neuonc\/nox038","DOI":"10.1093\/neuonc\/nox038"},{"key":"20_CR25","doi-asserted-by":"publisher","unstructured":"Mitchell LA, Lopez Espinoza F, Mendoza D, Kato Y, Inagaki A, Hiraoka K, et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol. 2017; https:\/\/doi.org\/10.1093\/neuonc\/nox037","DOI":"10.1093\/neuonc\/nox037"},{"key":"20_CR26","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1158\/1078-0432.CCR-06-1452","volume":"12","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Kimura T, Logg CR, Kasahara N. Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res. 2006;12:7108\u201316.","journal-title":"Clin Cancer Res"},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1158\/0008-5472.CAN-06-4673","volume":"67","author":"K Hiraoka","year":"2007","unstructured":"Hiraoka K, Kimura T, Logg CR, Tai CK, Haga K, Lawson GW, et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res. 2007;67:5345\u201353.","journal-title":"Cancer Res"},{"key":"20_CR28","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1158\/1078-0432.CCR-12-3735","volume":"19","author":"MJ Hickey","year":"2013","unstructured":"Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, et al. Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain. Clin Cancer Res. 2013;19:4137\u201348.","journal-title":"Clin Cancer Res"},{"key":"20_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073\u201381.","journal-title":"JAMA"},{"key":"20_CR30","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","volume":"18","author":"WF Regine","year":"2011","unstructured":"Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319\u201326.","journal-title":"Ann Surg Oncol"},{"key":"20_CR31","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640\u20138.","journal-title":"J Clin Oncol"},{"key":"20_CR32","doi-asserted-by":"publisher","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; https:\/\/doi.org\/10.1016\/s0140-6736(16)30583-9","DOI":"10.1016\/s0140-6736(16)30583-9"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/46.2.171","volume":"46","author":"A Vermes","year":"2000","unstructured":"Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46:171\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"20_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cgt.2016.65","volume":"24","author":"M Pergamo","year":"2017","unstructured":"Pergamo M, Miller G. Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Ther. 2017;24:100\u20135.","journal-title":"Cancer Gene Ther"},{"key":"20_CR35","doi-asserted-by":"publisher","first-page":"e998519","DOI":"10.1080\/2162402X.2014.998519","volume":"4","author":"S Karakhanova","year":"2015","unstructured":"Karakhanova S, Link J, Heinrich M, Shevchenko I, Yang Y, Hassenpflug M, et al. Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology. 2015;4:e998519.","journal-title":"Oncoimmunology"},{"key":"20_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/hgtb.2015.106","volume":"27","author":"CG Twitty","year":"2016","unstructured":"Twitty CG, Diago OR, Hogan DJ, Burrascano C, Ibanez CE, Jolly DJ, et al. Retroviral replicating vectors deliver cytosine deaminase leading to targeted 5-fluorouracil-mediated cytotoxicity in multiple human cancer types. Hum Gene Ther Methods. 2016;27:17\u201331.","journal-title":"Hum Gene Ther Methods"},{"key":"20_CR37","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651\u20139.","journal-title":"Mol Ther"},{"key":"20_CR38","doi-asserted-by":"publisher","first-page":"8302","DOI":"10.1073\/pnas.91.17.8302","volume":"91","author":"BE Huber","year":"1994","unstructured":"Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91:8302\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"20_CR39","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.ijrobp.2006.12.020","volume":"67","author":"JK Chen","year":"2007","unstructured":"Chen JK, Hu LJ, Wang D, Lamborn KR, Deen DF. Cytosine deaminase\/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys. 2007;67:1538\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"20_CR40","doi-asserted-by":"publisher","unstructured":"Huang T, Parab S, Burnett R, Diago O, Ostertag D, Hofman FM, et al. Intravenous administration of a retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in an orthotopic immune-competent mouse glioma model. Hum Gene Ther. 2014; https:\/\/doi.org\/10.1089\/hum.2014.100","DOI":"10.1089\/hum.2014.100"},{"key":"20_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/10430340050015770","volume":"11","author":"C Macdonald","year":"2000","unstructured":"Macdonald C, Walker S, Watts M, Ings S, Linch DC, Devereux S. Effect of changes in expression of the amphotropic retroviral receptor PiT-2 on transduction efficiency and viral titer: implications for gene therapy. Hum Gene Ther. 2000;11:587\u201395.","journal-title":"Hum Gene Ther"},{"key":"20_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1348-0421.2008.00040.x","volume":"52","author":"H Takeuchi","year":"2008","unstructured":"Takeuchi H, Matano T. Host factors involved in resistance to retroviral infection. Microbiol Immunol. 2008;52:318\u201325.","journal-title":"Microbiol Immunol"},{"key":"20_CR43","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1128\/JVI.68.12.8001-8007.1994","volume":"68","author":"Y Takeuchi","year":"1994","unstructured":"Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol. 1994;68:8001\u20137.","journal-title":"J Virol"},{"key":"20_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-065X.1999.tb01298.x","volume":"168","author":"WR Green","year":"1999","unstructured":"Green WR. Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape. Immunol Rev. 1999;168:271\u201386.","journal-title":"Immunol Rev"},{"key":"20_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1600-0463.2009.02450.x","volume":"117","author":"KC Williams","year":"2009","unstructured":"Williams KC, Burdo TH. HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. APMIS. 2009;117:400\u201312.","journal-title":"APMIS"},{"key":"20_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/hum.1990.1.1-15","volume":"1","author":"K Cornetta","year":"1990","unstructured":"Cornetta K, Moen RC, Culver K, Morgan RA, McLachlin JR, Sturm S, et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. 1990;1:15\u201330.","journal-title":"Hum Gene Ther"},{"key":"20_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/hum.1991.2.1-5","volume":"2","author":"K Cornetta","year":"1991","unstructured":"Cornetta K, Morgan RA, Anderson WF. Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther. 1991;2:5\u201314.","journal-title":"Hum Gene Ther"},{"key":"20_CR48","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/hum.2012.216","volume":"25","author":"AH Lin","year":"2014","unstructured":"Lin AH, Timberlake N, Logg CR, Liu Y, Kamijima S, Diago O, et al. MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response. Hum Gene Ther. 2014;25:759\u201371.","journal-title":"Hum Gene Ther"},{"key":"20_CR49","doi-asserted-by":"publisher","first-page":"10998","DOI":"10.1128\/JVI.01311-08","volume":"82","author":"E Takeda","year":"2008","unstructured":"Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, et al. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol. 2008;82:10998\u20131008.","journal-title":"J Virol"},{"key":"20_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1128\/JVI.01371-07","volume":"82","author":"EP Browne","year":"2008","unstructured":"Browne EP, Littman DR. Species-specific restriction of apobec3-mediated hypermutation. J Virol. 2008;82:1305\u201313.","journal-title":"J Virol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0020-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-018-0020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:09:48Z","timestamp":1684616988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-018-0020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":50,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1038\/s41417-018-0020-7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"13 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"D.J.J., and H.E.G. are employees of Tocagen. N.K. is a consultant. All three have an ownership interest in Tocagen. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}